NICE says Revlimid costs too much
This article was originally published in Scrip
Executive Summary
Celgene's Revlimid (lenalidomide) is not sufficiently cost-effective for routine treatment of multiple myeloma in the national health service in England and Wales, the National Institute for health and Clinical Excellencehas found. Draft guidance from the institute says lenalidomide in combination with dexamethasone is not recommended for the treatment of multiple myeloma in people who have received at least one prior therapy.